---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006720"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:57:06.876188+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics Q3 sales up 63% YoY to $27.3M; raises full-year 2025 guidance

## Summary
- Net sales $27.3M (+63% YoY); DME $21.0M (+45%), PBP $6.2M (+178%).
- Gross margin 55.5% (+212 bps); net loss $14.2M vs $9.7M prior year.
- Installed base 29,419 users (+162%); new patient starts 5,334 (+68%); 70% from MDI.
- Adjusted EBITDA -$12.2M (negative 45% of sales); cash $274.0M.
- Raised full-year 2025 guidance; specific numbers not disclosed in filing.

## SEC filing metadata
- accession: 0001171843-25-006720
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184325006720/0001171843-25-006720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184325006720/f8k_102825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006720
- JSON: https://secwatch.observer/filing/0001171843-25-006720.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.